Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Innovations in Syphilis Prevention in the United States: Reconsidering the Epidemiology and Involving Communities—Program Announcement 523; Meeting

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Disease, Disability, and Injury Prevention and Control SEP: Innovations in Syphilis Prevention in the United States: Reconsidering the Epidemiology and Involving Communities—Program Announcement 523.

Time and Dates: 8:30 a.m.–5:30 p.m., July 27–28, 1995.

Place: Corporate Square, Building 11, Conference Room A, 1413, Corporate Square Boulevard, Atlanta, Georgia 30329.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 523.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Contact Person for More Information: Richard Conlon, Acting Chief, Resource Analysis Office (E07), National Center for Prevention Services, CDC, 11 Corporate Square, Corporate Square Boulevard, Atlanta, Georgia, 30329, Telephone 404/639–8023.

Dated: June 14, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–15031 Filed 6–19–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95D–0115]

Compliance Policy Guides Manual; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a new bound edition of the ''FDA Compliance Policy Guides'' (CPG manual). The CPG manual is intended to provide guidance to FDA district offices by offering a convenient and organized system for statements of FDA compliance policy, including those statements which contain regulatory action guidance information.

ADDRESSES: The CPG manual may be ordered from National Technical Information Service (NTIS), U.S. Department of Commerce, 5285 Port Royal Rd., Springfield, VA 22161. Orders must reference NTIS order number PB95–915499 for each copy of the manual. Payment may be made by check, moneyorder, charge card (American Express, VISA, or Mastercard), or billing arrangements made with NTIS. Charge card orders must include the charge card account number and expiration date. For telephone orders or further information on placing an order, call NTIS at 703–487–4650. The CPG manual is available for public examination in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Barbara A. Rodgers, Office of Regulatory Affairs (HFC–230), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–0417.

SUPPLEMENTARY INFORMATION: FDA is issuing the new bound edition of the CPG manual to provide information on FDA compliance policy and internal guidance to FDA district offices in a more organized, convenient, and economical format. With the publication of this bound edition, the CPG manual has been reorganized into a general chapter and five program area chapters. The new CPG manual contains 500 individual guides; 227 of these have been revised and/or updated, and 26 of the guides have been deleted. This new bound edition of CPG's does not contain chapters 55 through 58, which contained memoranda of understanding (MOU's), interagency agreements (IAG's), and mutual recognition agreements (MRA's).

The statements made in the CPG manual are not intended to create or confer any rights, privileges, or benefits on or for any private person, but are intended merely for internal FDA guidance.

Dated: June 13, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–14948 Filed 6–19–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95F–0129]

Shell Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Shell Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of poly(oxy-1,2-ethanediyloxycarbonyl-2,6-naphthalenediylcarbonyl) polymer and the copolymer of poly(oxy-1,2-ethanediyloxycarbonyl-2,6-naphthalenediylcarbonyl) with ethylene terephthalate as components of articles intended for food-contact use.

DATES: Written comments on the petitioner's environmental assessment by July 20, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4451) has been filed by Shell Chemical Co., 130 Johns Ave., Akron, OH 44305–4097. The petition proposes to amend the food additive regulations in part 177 (21 CFR part 177) to provide for the safe use of poly(oxy-1,2-ethanediyloxycarbonyl-2,6-napthalenediylcarbonyl) polymer and the copolymer poly(oxy-1,2-ethanediyloxycarbonyl-2,6-naphthalenediylcarbonyl) with ethylene terephthalate as components of articles intended for food-contact use.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before July 20, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments